CNTX 0290

Drug Profile

CNTX 0290

Alternative Names: CNTX-0290

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Centrexion Therapeutics
  • Class Non-opioid analgesics
  • Mechanism of Action Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 18 Jul 2017 Centrexion has patent protection for CNTX 0290 in USA
  • 18 Jul 2017 Phase-I clinical trials in Pain (In adults, In the elderly) in USA (PO) before July 2017
  • 18 Jul 2017 Centrexion completes a phase I trial in Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top